Tiziana Life Sciences PLC Stock Price, News & Analysis (LON:TILS)

GBX 150 0.00 (0.00 %)
(As of 11/18/2017 04:00 PM ET)
Previous CloseGBX 150
Today's RangeGBX 150 - GBX 150
52-Week RangeGBX 102.06 - GBX 240
VolumeN/A
Average Volume1,374 shs
Market Capitalization£176.94 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Tiziana Life Sciences PLC (LON:TILS)

Tiziana Life Sciences PLC logoTiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. Its products in clinical stage include Milciclib and Foralumab. Its products in pre-clinical stage include TZLS-101 and TZLS-214. The Company is focused on its lead compound, Milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division, as well as a number of other protein kinases. Milciclib is in Phase II clinical trials for thymic carcinoma. The Company's Foralumab is a fully human engineered anti-human cluster of differentiation 3 (CD3) antibody. The Company is involved in the development of Bcl-3 inhibitors. The Company's lead clinical candidate, CB1, is a Bcl-3 inhibitor with potent anti-metastatic activity.


Industry, Sector and Symbol:
  • Industry: Investment Trusts
  • Sub-Industry: N/A
  • Sector: Investment Trusts
  • Symbol: LON:TILS
  • Previous Symbol: LON:ADI
  • CUSIP: N/A
  • Web: www.tizianalifesciences.com
Profitability:
  • Trailing EPS: GBX (0.09)
  • Return on Equity: -457.77%
  • Return on Assets: -208.53%
Misc:
  • Outstanding Shares: 123,830,000
 

Frequently Asked Questions for Tiziana Life Sciences PLC (LON:TILS)

What is Tiziana Life Sciences PLC's stock symbol?

Tiziana Life Sciences PLC trades on the London Stock Exchange (LON) under the ticker symbol "TILS."

How were Tiziana Life Sciences PLC's earnings last quarter?

Tiziana Life Sciences PLC (LON:TILS) announced its quarterly earnings results on Friday, September, 29th. The biotechnology company reported ($4.10) earnings per share for the quarter, missing analysts' consensus estimates of ($2.00) by $2.10. View Tiziana Life Sciences PLC's Earnings History.

Where is Tiziana Life Sciences PLC's stock going? Where will Tiziana Life Sciences PLC's stock price be in 2017?

1 Wall Street analysts have issued 12-month price objectives for Tiziana Life Sciences PLC's shares. Their predictions range from GBX 0.20 to GBX 0.20. On average, they anticipate Tiziana Life Sciences PLC's stock price to reach GBX 0.20 in the next twelve months. View Analyst Ratings for Tiziana Life Sciences PLC.

Who are some of Tiziana Life Sciences PLC's key competitors?

Who are Tiziana Life Sciences PLC's key executives?

Tiziana Life Sciences PLC's management team includes the folowing people:

  • Gabriele M. Cerrone, Executive Chairman of the Board (Age 42)
  • Kunwar Shailubhai Ph.D., Chief Executive Officer, Chief Scientific Officer, Director (Age 59)
  • Tiziano Lazzaretti, Chief Financial Officer
  • James Tripp, Chief Operating Officer, Head of Global Clinical Operations (Age 46)
  • P. Cooper, Company Secretary
  • Percy W. C. Lomax, Non-Executive Director
  • Willy Jules Simon, Non-Executive Director (Age 64)

How do I buy Tiziana Life Sciences PLC stock?

Shares of Tiziana Life Sciences PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Tiziana Life Sciences PLC's stock price today?

One share of Tiziana Life Sciences PLC stock can currently be purchased for approximately GBX 150.

How big of a company is Tiziana Life Sciences PLC?

Tiziana Life Sciences PLC has a market capitalization of £176.94 million.

How can I contact Tiziana Life Sciences PLC?

Tiziana Life Sciences PLC's mailing address is 3rd Fl, 11-12 St. James's Square, LONDON, SW1Y 4LB, United Kingdom. The biotechnology company can be reached via phone at +44-20-74952379.


MarketBeat Community Rating for Tiziana Life Sciences PLC (LON TILS)

Community Ranking:  1.3 out of 5 (star)
Outperform Votes:  39 (Vote Outperform)
Underperform Votes:  106 (Vote Underperform)
Total Votes:  145
MarketBeat's community ratings are surveys of what our community members think about Tiziana Life Sciences PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Tiziana Life Sciences PLC (LON:TILS)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 0 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: GBX 0.20

Consensus Price Target History for Tiziana Life Sciences PLC (LON:TILS)

Price Target History for Tiziana Life Sciences PLC (LON:TILS)

Analysts' Ratings History for Tiziana Life Sciences PLC (LON:TILS)

Show:
DateFirmActionRatingPrice TargetDetails
10/31/2017Beaufort SecuritiesReiterated RatingSpeculative BuyView Rating Details
(Data available from 11/19/2015 forward)

Earnings

Earnings History and Estimates Chart for Tiziana Life Sciences PLC (LON:TILS)

Earnings by Quarter for Tiziana Life Sciences PLC (LON:TILS)

Earnings History by Quarter for Tiziana Life Sciences PLC (LON TILS)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
9/29/2017S1 2017GBX (2)GBX (4.10)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Tiziana Life Sciences PLC (LON:TILS)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Tiziana Life Sciences PLC (LON:TILS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Tiziana Life Sciences PLC (LON TILS)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Tiziana Life Sciences PLC (LON TILS)

Source:
DateHeadline
How Does Investing In Tiziana Life Sciences PLC (AIM:TILS) Impact Your Portfolio?How Does Investing In Tiziana Life Sciences PLC (AIM:TILS) Impact Your Portfolio?
finance.yahoo.com - October 3 at 1:35 PM
Motif Bio Share ChatMotif Bio Share Chat
www.lse.co.uk - October 1 at 7:08 PM
2 small-cap growth stocks that could make you a millionaire2 small-cap growth stocks that could make you a millionaire
www.fool.co.uk - September 30 at 7:33 PM
Tiziana Life Sciences Interim Loss Widens In "Busy" First HalfTiziana Life Sciences Interim Loss Widens In "Busy" First Half
www.morningstar.co.uk - September 29 at 10:07 AM
Tiziana Life Sciences PLC (TILS) Releases Quarterly  Earnings Results, Misses Estimates By $2.10 EPSTiziana Life Sciences PLC (TILS) Releases Quarterly Earnings Results, Misses Estimates By $2.10 EPS
www.americanbankingnews.com - September 29 at 8:20 AM
Tiziana Life Sciences PLC (TILS) Receives Speculative Buy Rating from Beaufort SecuritiesTiziana Life Sciences PLC (TILS) Receives Speculative Buy Rating from Beaufort Securities
www.americanbankingnews.com - September 10 at 12:44 PM
A Proprietary Oral Formulation of Foralumab - London South East (registration) (blog)A Proprietary Oral Formulation of Foralumab - London South East (registration) (blog)
www.lse.co.uk - September 7 at 9:58 AM
Tiziana Life Sciences Develops Oral Formulation Of ForalumabTiziana Life Sciences Develops Oral Formulation Of Foralumab
www.morningstar.co.uk - September 6 at 9:10 AM
Beaufort Securities Reaffirms Speculative Buy Rating for Tiziana Life Sciences PLC (TILS)Beaufort Securities Reaffirms Speculative Buy Rating for Tiziana Life Sciences PLC (TILS)
www.americanbankingnews.com - August 20 at 5:02 PM
Publication of Research Article on Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy ... - Business Wire (press release)Publication of Research Article on Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy ... - Business Wire (press release)
www.businesswire.com - July 30 at 6:43 AM
Publication of Research Article on Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune DiseasesPublication of Research Article on Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune Diseases
finance.yahoo.com - July 28 at 8:48 AM
Tiziana Life Sciences PLC (LON:TILS) Receives "Speculative Buy" Rating from Beaufort SecuritiesTiziana Life Sciences PLC (LON:TILS) Receives "Speculative Buy" Rating from Beaufort Securities
www.americanbankingnews.com - July 23 at 10:48 AM
Tiziana Life Sciences Announces Initiation of a Phase IIa Clinical Trial with Milciclib in Patients with Hepatocellular CarcinomaTiziana Life Sciences Announces Initiation of a Phase IIa Clinical Trial with Milciclib in Patients with Hepatocellular Carcinoma
finance.yahoo.com - July 20 at 8:35 AM
Proposed changes to CLNs and Warrant Terms - London South East (registration) (blog)Proposed changes to CLNs and Warrant Terms - London South East (registration) (blog)
www.lse.co.uk - July 14 at 9:13 AM
Bcl-3 pre-clinical update and Directors dealing - London South East (registration) (blog)Bcl-3 pre-clinical update and Director's dealing - London South East (registration) (blog)
www.lse.co.uk - June 10 at 3:24 AM
Tiziana Life Sciences Stops Funding For Cardiff University Programme (ALLISS)Tiziana Life Sciences Stops Funding For Cardiff University Programme (ALLISS)
www.morningstar.co.uk - June 9 at 1:55 AM
Biotech Is Really Interested in 100-Year-Old ItaliansBiotech Is Really Interested in 100-Year-Old Italians
www.bloomberg.com - June 2 at 8:26 PM
Tiziana Life Sciences Announces Approval of a Phase II Clinical Trial Protocol for Milciclib in Patients with ... - Business Wire (press release)Tiziana Life Sciences Announces Approval of a Phase II Clinical Trial Protocol for Milciclib in Patients with ... - Business Wire (press release)
www.businesswire.com - April 26 at 3:17 PM
Warrant Expiry - Reminder - London South East (registration) (blog)Warrant Expiry - Reminder - London South East (registration) (blog)
www.lse.co.uk - January 18 at 12:30 AM
Tiziana Life Sciences In-Licenses NI-1201, a Fully Human anti-IL-6R Monoclonal Antibody - Business Wire (press release)Tiziana Life Sciences In-Licenses NI-1201, a Fully Human anti-IL-6R Monoclonal Antibody - Business Wire (press release)
www.businesswire.com - January 4 at 6:44 AM
Tiziana Life Sciences In-Licenses NI-1201, a Fully Human anti-IL-6R Monoclonal AntibodyTiziana Life Sciences In-Licenses NI-1201, a Fully Human anti-IL-6R Monoclonal Antibody
uk.finance.yahoo.com - January 3 at 9:18 AM
Half Year 2016 Tiziana Life Sciences PLC Earnings Release - Before Market OpenHalf Year 2016 Tiziana Life Sciences PLC Earnings Release - Before Market Open
biz.yahoo.com - September 29 at 10:19 AM
Tiziana Life Sciences PLC: Change of Registered OfficeTiziana Life Sciences PLC: Change of Registered Office
www.streetinsider.com - August 18 at 8:01 PM
Tiziana Life Sciences PLC Announces Exercise of Warrants, Conversion of Convertible Loan Notes and Issue of EquityTiziana Life Sciences PLC Announces Exercise of Warrants, Conversion of Convertible Loan Notes and Issue of Equity
www.marketwatch.com - June 29 at 10:31 AM
Full Year 2015 Tiziana Life Sciences PLC Earnings Release - Time Not SuppliedFull Year 2015 Tiziana Life Sciences PLC Earnings Release - Time Not Supplied
biz.yahoo.com - June 7 at 7:07 AM
Tiziana reveals possible new anti-cancer moleculeTiziana reveals possible new anti-cancer molecule
uk.finance.yahoo.com - January 8 at 4:25 AM

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Tiziana Life Sciences PLC (LON TILS) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.